Know Cancer

forgot password

A Phase 2 Study of AZD6244 in Relapsed or Refractory AML

Phase 2
18 Years
Open (Enrolling)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia

Thank you

Trial Information

A Phase 2 Study of AZD6244 in Relapsed or Refractory AML


I. To determine the response rate (includes complete response-CR, complete response with
incomplete count recovery CRi, partial response-PR, and minor response-MR) to AZD6244


I. To determine the effects of AZD6244 in AML samples on p-ERK and evaluate the potential
utility of p-ERK inhibition as a surrogate marker of biologic activity.

II. To correlate the effects of AZD6244 with the presence (or absence) of mutated RAS or
FLT-3 at baseline.

III. To assess the safety profile of AZD6244 in patients with AML.


Patients receive selumetinib orally (PO) twice daily (BID) on days 1 -28. Treatment repeats
every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 52 weeks.

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Relapsed or refractory acute myeloid leukemia (AML)

- Secondary AML including AML arising from antecedent hematologic diseases (e.g.,
myelodysplastic syndrome, myeloproliferative disorders, or therapy-related AML)

- Elderly patients ≥ 60 years of age, previously untreated, and who are not candidates
for or have refused standard chemotherapy are eligible for this trial

- Patients with relapsed acute promyelocytic leukemia (APL) who are FLT3+ and have
failed both tretinoin and arsenic therapy are eligible for this trial

- No known active CNS disease

- ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

- Total bilirubin ≤ 2 mg/dL (unless due to disease, hemolysis, or Gilbert disease)

- In patients with associated hemolysis or Gilbert disease, a bilirubin of > 2
mg/dL is allowed as a result of predominantly unconjugated hyperbilirubinemia

- AST/ALT < 3 times upper limit of normal

- Creatinine < 2 mg/dL

- Baseline pulse oximetry > 92%

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception prior to, during, and for 4 weeks
(16 week for males) after completion of study treatment

- Recovered from prior therapy

- At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
or radiotherapy

- Hydroxyurea may be administered for the first 7 days of therapy in patients with
rapidly rising white count (WBC > 20 K/μL)

- At least 4 weeks since prior investigational agents

- No prior MEK inhibitors

- No concurrent medication that can prolong the QT interval

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

Exclusion Criteria:

- History of allergic reactions attributed to compounds of similar chemical or
biological composition to AZD6244 or its excipient Captisol®

- QTc interval > 450 msecs or other factors that increase the risk of QT prolongation
or arrhythmic events (e.g., heart failure, hypokalemia, or family history of long QT
interval syndrome), including New York Heart Association class III or IV heart

- Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory
bowel disease), or significant bowel resection that would preclude adequate

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness or social situations that would limit compliance
with study requirements

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate (CR, CR with incomplete count recovery, partial response, and minor response) to AZD6244

Outcome Description:

A Simon, optimal two-stage design will be employed in cohort A. For Cohort B, we will determine the response rate and provide an exact 90% confidence interval using the binomial distribution. The response rate in these patients will be compared to that observed in the main cohort using Fisherâs exact test.

Outcome Time Frame:

Up to 52 weeks

Safety Issue:


Principal Investigator

Olatoyosi Odenike

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

December 2007

Completion Date:

Related Keywords:

  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
  • Adult Acute Promyelocytic Leukemia (M3)
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Recurrent Adult Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Neoplasms
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Promyelocytic, Acute
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Myelodysplastic-Myeloproliferative Diseases



University of Chicago Comprehensive Cancer Center Chicago, Illinois  60637-1470